DRMA
NASDAQDermata Therapeutics Inc.
News · 26 weeks32+100%
2026-03-012026-08-23
Mix1690d
- SEC Filings7(44%)
- Market5(31%)
- Insider3(19%)
- Other1(6%)
Latest news
25 items- NEWSDermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com -- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -- Consumers can purchase a one-month kit or subscribe for convenient recurring delivery - SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now availa
- NEWSDermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch- Preorders can be made by visiting www.tomeskincare.com -- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -- Tome Foundational Treatment is a once-weekly topical mask for skin renewal - SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.Beginning today, customers can preorder Tome Foundational Treatment at www.tomeskin
- INSIDERPRESIDENT, CHAIRMAN, CEO Proehl Gerald T was granted 170,068 shares (SEC Form 4)4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
- INSIDERSVP, CFO Van Hoose Kyri K. was granted 102,040 shares, increasing direct ownership by 78% to 232,463 units (SEC Form 4)4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
- SECSEC Form 25-NSE filed by Dermata Therapeutics Inc.25-NSE - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- NEWSDermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), series E warrants to purchase up to 2,293,608 shares of common stock and short-term series F warrants to purchase up to 2,293,608 shares of common stock at a purchase price of $1.46 per share of common stoc
- NEWSDermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026."Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company," commented Gerry Proehl, Derma
- SECSEC Form 10-Q filed by Dermata Therapeutics Inc.10-Q - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- NEWSDermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment- A new chapter in skincare has arrived -- This will be Dermata's first commercial product launch, planned for August 25, 2026 -- Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newswire / August 5, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, with those on the waitlist getting early access to preorder. The launch of the Foundational Treatment represents a significant milestone in Dermata's strategic evolution toward becoming a consumer-focused, rev
- INSIDERDirector Scott Kathleen D. sold $13 worth of shares (11 units at $1.19), closing all direct ownership in the company (SEC Form 4)4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
- SECSEC Form S-8 filed by Dermata Therapeutics Inc.S-8 - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECSEC Form EFFECT filed by Dermata Therapeutics Inc.EFFECT - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECSEC Form 424B3 filed by Dermata Therapeutics Inc.424B3 - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECAmendment: SEC Form S-3/A filed by Dermata Therapeutics Inc.S-3/A - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECSEC Form 10-Q filed by Dermata Therapeutics Inc.10-Q - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- NEWSDermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 -- Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility - SAN DIEGO, CA / ACCESS Newswire / May 13, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026."Since announcing our strategic pivot in September 2025, we have m
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECSEC Form DEFA14A filed by Dermata Therapeutics Inc.DEFA14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECSEC Form DEF 14A filed by Dermata Therapeutics Inc.DEF 14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
DRMA FAQ
7 questionsWhat does Dermata Therapeutics Inc. do?
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.Where does DRMA stock trade?
Dermata Therapeutics Inc. (DRMA) is listed on NASDAQ.What sector and industry is DRMA in?
Dermata Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dermata Therapeutics Inc. go public?
Dermata Therapeutics Inc. (DRMA) completed its IPO in 2021.What are analysts saying about DRMA?
Dermata Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Brookline Capital: Buy with a $1400.00 price target on 2021-09-21. Recent price targets range from $900.00 to $1400.00.What companies are similar to DRMA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DRMA side-by-side with any of them on Quantisnow.How can I track DRMA on Quantisnow?
Quantisnow aggregates Dermata Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRMA to receive live email and push alerts on every new disclosure.